Evaluation of the Clinical Utility of the Bone Metastases Ensemble Trees for Survival Decision Support Platform (BMETS-DSP): A Case-Based Pilot Assessment Data on 221 newly diagnosed patients with AML ...

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with ...

Please provide your email address to receive an email when new articles are posted on . The addition of azacitidine to venetoclax significantly improved response rates and OS among certain patients ...

The investigational anti-CD47 monoclonal antibody magrolimab combined with azacitidine showed promising efficacy and was well tolerated in patients with untreated higher-risk myelodysplastic syndromes ...

A phase 3 trial evaluating ivosidenib plus azacitidine in adults with previously untreated IDH1-mutated AML showed that it met all endpoints. Positive results from a phase 3 trial evaluating ...

Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response ...

ORLANDO, Florida — For the first time, there is a maintenance therapy for patients with acute myeloid leukemia (AML) in remission that can improve overall survival — a new oral formulation of an old ...

The alternative text for this image may have been generated using AI. To the best of our knowledge, our two cases are the first reported cases that showed a very good response to 5-azacitidine in the ...

The phase 3 VERONA trial did not meet the primary endpoint of overall survival. Topline data were announced from a phase 3 trial evaluating venetoclax (Venclexta ®) plus azacitidine for patients with ...

Please provide your email address to receive an email when new articles are posted on . The analysis included treatment-naive patients with AML who had been deemed unfit for intensive chemotherapy ...

Phosphoinositide-phospholipase C (PI-PLC) beta1 can be considered a specific target for demethylating therapy in high-risk myelodysplastic syndrome (MDS) patients, as azacitidine treatment has been ...

Details concerning the Azacitidine medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.